ResMed CEO sells 4,991 shares after option exercise

ResMed’s CEO exercised 4,991 options and sold the resulting shares under a pre-arranged Rule 10b5-1 trading plan.

Rhea-AI Filing Summary

RESMED INC (RMD) reported that Chairman and CEO Michael J. Farrell exercised stock options for 4,991 shares of ResMed common stock on September 8, 2026, at an exercise price of $146.34 per share and sold the same 4,991 shares at a weighted average price of $222.44 per share. The transactions were conducted under a Rule 10b5-1 trading plan adopted October 31, 2024. After the option exercise, Farrell held 9,984 stock options directly and 2,090 shares indirectly through the Lisette and Michael Farrell Family Trust.

Insider Trade Summary 10b5-1

Exercise and Sale: 4,991 shares ($380K approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Farrell Michael J.

Role Chairman and CEO

Sold 4,991 shs ($1.11M)

Approx. gross sale proceeds $1.11M

Approx. exercise cost $730K

Approx. pre-tax spread $380K

Type	Security	Shares	Price	Value
Exercise	ResMed Common Stock Options F1, F3	4,991	$0.00	$0.00
Exercise	ResMed Common Stock F1	4,991	$146.34	$730K
Sale	ResMed Common Stock F1, F2	4,991	$222.4385	$1.11M
holding	ResMed Common Stock	--	--	--

Holdings After Transaction: ResMed Common Stock Options — 9,984 contracts (Direct); ResMed Common Stock — 466,256 shares (Direct); ResMed Common Stock — 2,090 shares (Indirect, Lisette and Michael Farrell Family Trust)

Footnotes (3)

1. F1. The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
2. F2. This transaction was executed in multiple trades at prices ranging from $220.680 - $225.390. The price reported above reflects the weighted average sale price.
3. F3. Represents date options first become exercisable. Options vest 1/3 per year.

Key Figures

Options exercised: 4,991 options Exercise price: $146.34 per share Shares sold: 4,991 shares +4 more

7 metrics

Options exercised 4,991 options Stock options for ResMed common stock exercised on September 8, 2026

Exercise price $146.34 per share Price paid to exercise the 4,991 stock options

Shares sold 4,991 shares ResMed common stock sold on September 8, 2026

Weighted average sale price $222.44 per share Weighted average price for sales between $220.68 and $225.39

Options held after transaction 9,984 options Directly held ResMed stock options following the reported exercise

Indirect shareholding 2,090 shares ResMed common stock held through the Lisette and Michael Farrell Family Trust

Rule 10b5-1 plan adoption date October 31, 2024 Date the trading plan governing these transactions was adopted

Key Terms

Rule 10b5-1 plan, weighted average sale price, vest

3 terms

Rule 10b5-1 plan regulatory

"The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

vest financial

"Represents date options first become exercisable. Options vest 1/3 per year."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RMD CEO Michael J. Farrell report on September 8, 2026?

Michael J. Farrell exercised 4,991 stock options for ResMed common stock at $146.34 per share on September 8, 2026, and received 4,991 shares of common stock as a result of this option exercise.

How many ResMed (RMD) shares did the CEO sell and at what price?

On September 8, 2026, Michael J. Farrell sold 4,991 shares of ResMed common stock at a weighted average price of $222.44 per share, with individual trade prices ranging from $220.68 to $225.39.

Were the September 8, 2026 ResMed (RMD) insider trades under a Rule 10b5-1 plan?

Yes. The filing states the transactions were conducted under a Rule 10b5-1 plan that was adopted on October 31, 2024, indicating they were pre-arranged rather than opportunistic trades.

How many ResMed (RMD) stock options does the CEO hold after this transaction?

After the September 8, 2026 option exercise, Michael J. Farrell directly held 9,984 stock options for ResMed common stock, according to the reported post-transaction holdings for the derivative securities.

Does the ResMed (RMD) CEO have any indirect shareholdings after this Form 4?

Yes. The report shows an indirect holding of 2,090 ResMed common shares held through the Lisette and Michael Farrell Family Trust, in addition to his direct derivative holdings.

What are the key dates and vesting terms of the ResMed (RMD) options exercised?

The exercised options first became exercisable on November 11, 2020 and vest one-third per year. They have an expiration date of November 21, 2026, as disclosed in the option detail footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 06:41 AM Accepted by SEC EDGAR 09/10/2026 - 06:40 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farrell Michael J.

(Last) (First) (Middle)

RESMED INC.

9001 SPECTRUM CENTER BLVD

(Street)

SAN DIEGO CALIFORNIA 92123

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock	09/08/2026		M(1)		4,991	A	$146.34	471,247	D
ResMed Common Stock	09/08/2026		S(1)		4,991	D	$222.4385(2)	466,256	D
ResMed Common Stock								2,090	I	Lisette and Michael Farrell Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
ResMed Common Stock Options	$146.34	09/08/2026		M(1)			4,991	11/11/2020(3)	11/21/2026	ResMed Common Stock	4,991	$0	9,984	D

Explanation of Responses:

1. The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.

2. This transaction was executed in multiple trades at prices ranging from $220.680 - $225.390. The price reported above reflects the weighted average sale price.

3. Represents date options first become exercisable. Options vest 1/3 per year.

	/s/ Michael J. Farrell, Chairman and CEO	09/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)